Mark B. Kaye's most recent trade in Conmed Corp. was a trade of 152 Common Stock done . Disclosure was reported to the exchange on Feb. 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Conmed Corp | Mark B. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 152 | 152 (0%) | 0% | 0 | Common Stock | |
| Conmed Corp | Mark B. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 152 | 0 | - | - | RSUs (Restricted Stock Units) | |
| Elevance Health | Mark B. Kaye | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 340.24 per share. | 02 Oct 2025 | 2,895 | 16,082 (0%) | 0% | 340.2 | 984,995 | Common Stock |
| Conmed Corp | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 8,061 | 8,061 | - | - | Options To Purchase Common Stock | |
| Conmed Corp | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 668 | 668 | - | - | RSUs (Restricted Stock Units) | |
| Elevance Health | Mark B. Kaye | EVP & CFO | Sale of securities on an exchange or to another person at price $ 424.82 per share. | 24 Apr 2025 | 4,588 | 18,977 (0%) | 0% | 424.8 | 1,949,074 | Common Stock |
| Elevance Health | Mark B. Kaye | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 13,713 | 13,713 | - | - | Employee Stock Option (Right to Buy) | |
| Elevance Health | Mark B. Kaye | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 3,604 | 23,565 (0%) | 0% | 0 | Common Stock | |
| Elevance Health | Mark B. Kaye | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 395.50 per share. | 03 Mar 2025 | 270 | 19,961 (0%) | 0% | 395.5 | 106,785 | Common Stock |
| Conmed Corp | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 1,846 | 1,846 | - | - | Options To Purchase Common Stock | |
| Conmed Corp | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 152 | 152 | - | - | RSUs (Restricted Stock Units) | |
| Elevance Health | Mark B. Kaye | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 505.16 per share. | 02 Oct 2024 | 2,818 | 20,213 (0%) | 0% | 505.2 | 1,423,541 | Common Stock |
| Elevance Health | Mark Kaye B. | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 10,633 | 10,633 | - | - | Employee Stock Option (Right to Buy) | |
| Elevance Health | Mark Kaye B. | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 2,755 | 23,031 (0%) | 0% | 0 | Common Stock |